Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Want to see JSPR full AI Analyst Report?
Top Page
Jasper Therapeutics
(NASDAQ:JSPR)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.80
▼(-21.18% Downside)
Action:ReiteratedDate:04/16/26
The score is primarily constrained by weak financial performance—no revenue, large operating losses, and heavy ongoing cash burn alongside a sharply reduced equity base. Technicals add pressure with a broader downtrend (below key moving averages and negative MACD), while valuation is difficult to assess due to negative earnings and no dividend support.
Positive Factors
Focused therapeutic pipeline
Jasper’s clear scientific focus on mast-cell biology and a lead anti-c-Kit monoclonal antibody (briquilimab/JSP191) represents a durable strategic advantage: a concentrated pipeline can create deep domain expertise, efficient R&D prioritization, and a clearer path to market if clinical proof-of-concept is achieved.
Negative Factors
No revenue and widening operating losses
The company reports no product revenue while operating losses have materially increased, indicating the core business is not self-sustaining. Over months to years this structural deficit forces dependence on external capital and makes long-term viability contingent on clinical or licensing success.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused therapeutic pipeline
Jasper’s clear scientific focus on mast-cell biology and a lead anti-c-Kit monoclonal antibody (briquilimab/JSP191) represents a durable strategic advantage: a concentrated pipeline can create deep domain expertise, efficient R&D prioritization, and a clearer path to market if clinical proof-of-concept is achieved.
Read all positive factors
Jasper Therapeutics (JSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.03M
Dividend YieldN/A
Average Volume (3M)399.98K
Price to Earnings (P/E)―
Beta (1Y)2.39
Revenue GrowthN/A
EPS Growth5.45%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding27,996,819
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.58
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$8.13Price Target Upside696.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Jasper Therapeutics Business Overview & Revenue Model
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell...
How the Company Makes Money
null...
Jasper Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -82.83M | -74.87M | -67.75M | -50.22M | -36.46M |
| Net Income | -75.80M | -71.27M | -64.47M | -37.69M | -30.64M |
Balance Sheet | |||||
| Total Assets | 35.78M | 79.90M | 94.89M | 48.36M | 93.65M |
| Cash, Cash Equivalents and Short-Term Investments | 28.69M | 71.64M | 86.89M | 38.25M | 84.70M |
| Total Debt | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M |
| Total Liabilities | 31.63M | 18.23M | 16.45M | 12.37M | 24.14M |
| Stockholders Equity | 4.15M | 61.67M | 78.44M | 35.99M | 69.52M |
Cash Flow | |||||
| Free Cash Flow | -77.17M | -63.15M | -52.33M | -46.43M | -36.11M |
| Operating Cash Flow | -77.16M | -62.60M | -52.07M | -45.86M | -33.68M |
| Investing Cash Flow | 5.00K | -532.00K | -267.00K | -576.00K | -2.43M |
| Financing Cash Flow | 34.21M | 47.88M | 100.97M | 55.00K | 100.97M |
Jasper Therapeutics Technical Analysis
Negative
1.02
Price Trends
1.16
Negative
1.42
Negative
2.06
Negative
Market Momentum
-0.07
Negative
50.84
Neutral
83.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 1.02 is above the 20-day moving average (MA) of 0.93, below the 50-day MA of 1.16, and below the 200-day MA of 2.06, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 83.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.
Jasper Therapeutics Risk Analysis
Jasper Therapeutics disclosed 82 risk factors in its most recent earnings report. Jasper Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jasper Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $265.70M | -1.25 | -60.22% | ― | -100.00% | -16.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $64.15M | -8.24 | 26.10% | ― | ― | ― | |
48 Neutral | $76.10M | -0.50 | -82.96% | ― | ― | 15.32% | |
45 Neutral | $113.50M | -6.36 | -236.85% | ― | -14.62% | 72.19% | |
43 Neutral | $27.57M | -1.93 | -226.10% | ― | ― | 63.57% | |
42 Neutral | $26.03M | -0.46 | -191.12% | ― | ― | 5.45% |
* Healthcare Sector Average
JSPR
Jasper Therapeutics
0.93
-4.22
-81.96%
CVM
Cel-Sci
3.04
-5.66
-65.06%
BYSI
Beyondspring
1.51
-0.04
-2.58%
CBUS
Cibus
1.42
-0.54
-27.55%
ACET
Adicet Bio
7.67
-2.29
-22.95%
ARTV
Artiva Biotherapeutics, Inc.
9.07
6.62
270.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.